Login to Your Account



NovImmune, Serono Enter Antibody Deal Worth $122M

By Cormac Sheridan


Wednesday, May 18, 2005
NovImmune SA entered its first product out-licensing pact, a deal with Serono SA, which is potentially worth up to $122 million for two preclinical fully human antibodies, NI-0401 and NI-0501. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription